JP2023528561A - 宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤 - Google Patents

宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤 Download PDF

Info

Publication number
JP2023528561A
JP2023528561A JP2022560025A JP2022560025A JP2023528561A JP 2023528561 A JP2023528561 A JP 2023528561A JP 2022560025 A JP2022560025 A JP 2022560025A JP 2022560025 A JP2022560025 A JP 2022560025A JP 2023528561 A JP2023528561 A JP 2023528561A
Authority
JP
Japan
Prior art keywords
cells
patient
cannabidiol
interferon
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528561A5 (OSRAM
Inventor
マーチャント，シュリーマ
パテル，マニット
エレーヌ ダンカン，ロビン
アナント ジャダブ，ビシャル
フェルナンダ デ アンドレード フェルナンデス，マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akseera Pharma Corp
Original Assignee
Akseera Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseera Pharma Corp filed Critical Akseera Pharma Corp
Publication of JP2023528561A publication Critical patent/JP2023528561A/ja
Publication of JP2023528561A5 publication Critical patent/JP2023528561A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022560025A 2020-03-29 2021-03-30 宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤 Pending JP2023528561A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021013770 2020-03-29
IN202021013770 2020-03-29
IN202021030633 2020-07-18
IN202021030633 2020-07-18
IN202021054151 2020-12-12
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (2)

Publication Number Publication Date
JP2023528561A true JP2023528561A (ja) 2023-07-05
JP2023528561A5 JP2023528561A5 (OSRAM) 2024-08-16

Family

ID=77927896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560025A Pending JP2023528561A (ja) 2020-03-29 2021-03-30 宿主細胞の分子および細胞メカニズムとＳＡＲＳ－ＣｏＶ－２タンパク質との相互作用、およびＣＯＶＩＤ－１９を治療するための製剤

Country Status (9)

Country Link
US (1) US20240226120A1 (OSRAM)
EP (1) EP4126913A4 (OSRAM)
JP (1) JP2023528561A (OSRAM)
CN (1) CN115968375A (OSRAM)
AU (1) AU2021247269A1 (OSRAM)
BR (1) BR112022019649A2 (OSRAM)
IL (1) IL296892A (OSRAM)
MX (1) MX2022012165A (OSRAM)
WO (1) WO2021199078A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
CN115531315B (zh) * 2022-12-05 2023-04-07 上海惠盾因泰生物科技有限公司 重组人干扰素λ1鼻喷雾剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
US10456435B2 (en) * 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
WO2020257588A1 (en) * 2019-06-20 2020-12-24 Shaman Naturals, Llc Compositions for preventing and treating viral infections
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
US11338010B2 (en) * 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
EP4149445A1 (en) * 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Uses and formulations of cannabinoids
WO2021231810A1 (en) * 2020-05-14 2021-11-18 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIORXIV [PREPRINT], JPN6025017903, 10 March 2021 (2021-03-10), pages 1 - 15, ISSN: 0005722534 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, JPN6025017908, 16 July 2020 (2020-07-16), pages 4967 - 4970, ISSN: 0005722536 *
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 168, JPN6025017905, 5 December 2020 (2020-12-05), pages 474 - 485, ISSN: 0005722535 *

Also Published As

Publication number Publication date
EP4126913A2 (en) 2023-02-08
WO2021199078A2 (en) 2021-10-07
AU2021247269A1 (en) 2022-12-01
WO2021199078A3 (en) 2021-12-09
CN115968375A (zh) 2023-04-14
US20240226120A1 (en) 2024-07-11
IL296892A (en) 2022-12-01
MX2022012165A (es) 2023-01-24
EP4126913A4 (en) 2024-09-18
BR112022019649A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
Sadri Nahand et al. Virus, exosome, and MicroRNA: new insights into autophagy
US20120190676A1 (en) Inhibitors of mtor kinase as anti-viral agents
US20240024337A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
WO2015157223A1 (en) Methods of treating coronavirus infection
US20240226120A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
WO2017117006A1 (en) Use of a dhodh inhibitor in combination with an inhibitor of pyrimidine salvage
US20200123127A1 (en) Removal of senescence-associated macrophages
CN113679726A (zh) 丹参提取物和醌类化合物在抗冠状病毒中的应用
US12544388B2 (en) Compound for treating and/or preventing diseases caused by coronavirus and use thereof
US20230201244A1 (en) Compositions and methods for preventing and/or treating microbial infections
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
Silva et al. Autophagy modulators in coronavirus diseases: a double strike in viral burden and inflammation
Nabi-Afjadi et al. A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? MN Afjadi et al.
Yang et al. Targeting intracellular Neu1 for coronavirus infection treatment
Elkholy et al. Ivermectin: a closer look at a potential remedy
Cursaro et al. A Focus on Natural Autophagy Modulators as Potential Host‐Directed Weapons Against Emerging and Re‐Emerging Viruses
Teixeira et al. The mTOR pathway as a target for SARS-COV-2: Rapamycin as a possible alternative pharmacological therapeutic for COVID-19
WO2021252099A2 (en) Antimicrobial and antitoxin compositions and methods for treatment
US20220323402A1 (en) Treatment, amelioration or prevention of a viral infection
Kandimalla et al. Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2
CA3195286A1 (en) Compositions and methods for treating acute respiratory failure and/or acute respiratory distress syndrome using tetrahydrocannabinol and compositions including same
Mahajan et al. Recent Advancements in the Delivery of Therapeutic Agents Targeting RNA-dependent RNA Polymerase of SARS-CoV-2
Tolulope Discovery of OJT009 as a Novel Inhibitor of Severe Acute Respiratory Syndrome Coronavirus 2 Infection for Potential Treatment of COVID-19
TWI800146B (zh) 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途
Khales et al. Amlodipine and diltiazem significantly repress human rotavirus infection in vitro

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104